VITALISScETM includes patients with elevated levels of CRP, ESR or KL-6, indicating active inflammation or progressive ILD.33, –35 By including these criteria, the VITALISScETM study is enriched for patients who are potentially at risk for disease progression. This evidence concerns the gene MUC1 and interstitial lung disease.